UG United-Guardian

United-Guardian, Inc. develops and manufactures pharmaceuticals, cosmetic ingredients, personal and health care products and medical devices. The firm conducts research and product development related to the development of new and unique cosmetic and personal care products. The company was founded by Alfred R. Globus in 1942 and is headquartered in Hauppauge, NY.

Company profile

UG stock data



13 May 21
28 Jul 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
19 Feb 21 Kenneth H Globus Common Stock Gift Dispose G Yes No 0 8,400 0 1,318,053
5 Mar 20 Kenneth H Globus Common Stock Gift Dispose G Yes No 0 8,000 0 1,334,853

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

25.9% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 29 28 +3.6%
Opened positions 3 4 -25.0%
Closed positions 2 3 -33.3%
Increased positions 6 3 +100.0%
Reduced positions 8 12 -33.3%
13F shares
Current Prev Q Change
Total value 18.87M 17.51M +7.8%
Total shares 1.19M 1.22M -2.2%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Renaissance Technologies 262.26K $3.97M -2.2%
GBL Gamco Investors 148.3K $2.25M 0.0%
Vanguard 128.83K $1.95M 0.0%
Rodgers Brothers 114.35K $1.73M +2.2%
Dimensional Fund Advisors 109.92K $1.67M -0.3%
Parthenon 71.27K $1.08M 0.0%
TETAA Teton Advisors 70.51K $1.07M +0.7%
ATAC Neuberger Berman 46.78K $709K -15.8%
Gabelli Funds 38K $576K 0.0%
BLK Blackrock 32.1K $486K +7.3%
Largest transactions
Shares Bought/sold Change
Anson Funds Management 0 -21.07K EXIT
Bridgeway Capital Management 29.5K +10K +51.3%
ATAC Neuberger Berman 46.78K -8.8K -15.8%
Renaissance Technologies 262.26K -5.86K -2.2%
Acadian Asset Management 1.75K -3.95K -69.3%
Rodgers Brothers 114.35K +2.5K +2.2%
BLK Blackrock 32.1K +2.17K +7.3%
California Public Employees Retirement System 14.42K -1.14K -7.3%
UBS UBS Group AG - Registered Shares 15.62K -901 -5.5%
Tower Research Capital 154 -562 -78.5%

Financial report summary

Management Discussion
  • Net sales for the first quarter of 2021 increased by $107,954 (approximately 3%) as compared with the first quarter of 2020. The increase in sales for the first quarter of 2021 was primarily attributable to an increase in sales of the Company’s pharmaceutical products and medical products, which was partially offset by a decrease in sales of the Company’s cosmetic ingredients and industrial products. The changes in the sales of the products in the Company’s different products lines were as follows:
  • The decrease in cosmetic ingredient sales to ASI was partially offset by an increase in sales of those products to the Company’s marketing partners in the UK, Italy, and Switzerland, which increased by a total of $100,520 (approximately 107%) compared with the first quarter of 2020. In addition, there was an increase of $14,470 in direct sales to three cosmetic ingredient customers in the United States during the first quarter of 2021.
  • Based on information received from ASI, the Company believes that the decrease in sales to ASI was primarily due to the impact of the pandemic on ASI’s customers, particularly in China. The decrease in ASI sales in China was the result of a number of factors, including (a) lower consumer demand in China for many of the products in which the Company’s products are used; (b) manufacturing disruptions in China resulting from the impact of the coronavirus on manufacturing facilities; and (c) excess inventory levels of the Company’s products resulting from overstocking on the part of ASI during 2020 due to the uncertainty of being able to obtain product from the Company during the pandemic. Since the Company’s cosmetic ingredients are marketed globally by its marketing partners in many different countries, and since the virus continues to impact countries at different times and to very different extents, it is difficult to project the future impact of the coronavirus pandemic on the Company’s global cosmetic ingredient sales. Until the global crisis passes it is likely that there will continue to be a negative impact on the Company’s sales of its cosmetic ingredients, as well as, to a lesser extent, its non-pharmaceutical medical products. However, based on sales in the first quarter of 2021, the Company believes that sales of its cosmetic ingredients are improving, and will continue to improve during 2021 as long as the global pandemic situation improves rather than worsens.
Content analysis
H.S. sophomore Avg
New words: Agreement, area, bring, burdensome, CGDP, claimed, closure, CMS, Coverage, decided, dedicated, deeply, degree, Discount, discounted, dollar, domestic, driven, elimination, equal, ERC, Euro, felt, FSS, Gap, handling, hopeful, incorporate, incorporated, intention, law, losing, modified, October, overly, position, prepaid, Program, proportional, qualified, rebate, reformulation, refund, refundable, refunded, request, resolved, Retention, significantly, stabilize, strong, Supply, terminate, terminated, termination, typically, weakening
Removed: adjusted, aggressively, allocated, amended, attract, authorized, began, Board, closed, commensurate, compete, comprehensive, debt, delayed, eligible, essential, Europe, fulfill, Governor, hereinafter, high, implementation, Korea, Korean, large, LEGAL, maintaining, MINE, moving, November, operate, passed, payable, permitted, problem, profit, projected, qualitative, quantitative, receiving, resume, retain, SAFETY, SENIOR, shut, simplify, slower, small, spread, temporary, transitioning, UNREGISTERED, variable, vast